Daniel S. Bradford

Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts

Gerard A. Silvestri, Paul J. Nietert, James S. Zoller et al. · Thorax · 2006 · 174 citations · Full text

Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Petr Zatloukal, Dae Seog Heo, K. Park et al. · Journal of Clinical Oncology · 2009 · 122 citations

First-line Platinum-based Therapy, Cancer Management, Pathology +17

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

Mark M. Awad, Q.S-C. Chu, Leena Gandhi et al. · Lung Cancer · 2016 · 62 citations

Bi 2536, Medicine, Pathology +9

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

Thomas E. Stinchcombe, Amy H. Peterman, Carrie B. Lee et al. · Journal of Thoracic Oncology · 2011 · 36 citations · Full text

Oncology, Elderly Patients, Medicine +7

Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116

Erin M. Casey, Wael A. Harb, Daniel S. Bradford et al. · Journal of Thoracic Oncology · 2010 · 25 citations · Full text

Chemonaïve Patients, Medicine, Pharmacology +8